Umeå University's logo

umu.sePublikasjoner
Endre søk
Link to record
Permanent link

Direct link
Schmitt-Egenolf, MarcusORCID iD iconorcid.org/0000-0002-3858-8474
Publikasjoner (10 av 81) Visa alla publikasjoner
Löfvendahl, S., Norlin, J. M. & Schmitt-Egenolf, M. (2023). Comorbidities in palmoplantar pustulosis: a Swedish population-based register study [Letter to the editor]. British Journal of Dermatology, 189(2), 230-232
Åpne denne publikasjonen i ny fane eller vindu >>Comorbidities in palmoplantar pustulosis: a Swedish population-based register study
2023 (engelsk)Inngår i: British Journal of Dermatology, ISSN 0007-0963, E-ISSN 1365-2133, Vol. 189, nr 2, s. 230-232Artikkel i tidsskrift, Letter (Fagfellevurdert) Published
sted, utgiver, år, opplag, sider
Oxford University Press, 2023
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-212408 (URN)10.1093/bjd/ljad134 (DOI)001002219700001 ()37285288 (PubMedID)2-s2.0-85165223045 (Scopus ID)
Tilgjengelig fra: 2023-07-28 Laget: 2023-07-28 Sist oppdatert: 2023-07-28bibliografisk kontrollert
Löfvendahl, S., Norlin, J. M. & Schmitt-Egenolf, M. (2023). Comorbidities in patients with generalized pustular psoriasis: a nationwide population-based register study [Letter to the editor]. The Journal of American Academy of Dermatology, 88(3), 736-738
Åpne denne publikasjonen i ny fane eller vindu >>Comorbidities in patients with generalized pustular psoriasis: a nationwide population-based register study
2023 (engelsk)Inngår i: The Journal of American Academy of Dermatology, ISSN 0190-9622, E-ISSN 1097-6787, Vol. 88, nr 3, s. 736-738Artikkel i tidsskrift, Letter (Fagfellevurdert) Published
sted, utgiver, år, opplag, sider
Elsevier, 2023
Emneord
case-control, comorbidities, epidemiology, generalized pustular psoriasis, healthcare register, population-based
HSV kategori
Forskningsprogram
dermatologi och venereologi
Identifikatorer
urn:nbn:se:umu:diva-200422 (URN)10.1016/j.jaad.2022.09.049 (DOI)000949235700001 ()36228948 (PubMedID)2-s2.0-85141807940 (Scopus ID)
Tilgjengelig fra: 2022-10-19 Laget: 2022-10-19 Sist oppdatert: 2023-05-02bibliografisk kontrollert
Löfvendahl, S., Norlin, J. M. & Schmitt-Egenolf, M. (2023). Economic burden of palmoplantar pustulosis in Sweden: a population-based register study. Acta Dermato-Venereologica, 103, Article ID adv00843.
Åpne denne publikasjonen i ny fane eller vindu >>Economic burden of palmoplantar pustulosis in Sweden: a population-based register study
2023 (engelsk)Inngår i: Acta Dermato-Venereologica, ISSN 0001-5555, E-ISSN 1651-2057, Vol. 103, artikkel-id adv00843Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The aim of this study was to estimate the economic burden of palmoplantar pustulosis, a chronic relapsing skin condition commonly occurring in combination with psoriasis vulgaris. Using data from the Swedish National Patient Register and Swedish Prescribed Drug Register for 2015, the study estimated all-cause and palmoplantar pustulosis-specific healthcare resource use (inpatient stays, physician visits and drug use) for 14,715 patients with palmoplantar pustulosis, and compared these both with matched controls from the general population and with patients with psoriasis vulgaris (without palmoplantar pustulosis). Mean annual direct costs for a patient with palmoplantar pustulosis was higher compared with costs for the general population (3,000 vs 1,700 Euro, p < 0.001). Compared with psoriasis vulgaris, more patients with palmoplantar pustulosis had inpatient stays, but fewer had physician visits and psoriasis-related drugs; the overall costs were similar. Only a small fraction of the costs of physician visits and inpatient stays for patients with palmoplantar pustulosis were attributable to specific palmoplantar pustulosis problems, indicating a clear comorbidity burden in palmoplantar pustulosis.

sted, utgiver, år, opplag, sider
Medical Journals Sweden, 2023
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-203551 (URN)10.2340/actadv.v103.4501 (DOI)000926022500007 ()36621923 (PubMedID)2-s2.0-85145970985 (Scopus ID)
Tilgjengelig fra: 2023-01-19 Laget: 2023-01-19 Sist oppdatert: 2023-09-05bibliografisk kontrollert
Ericson, O., Löfvendahl, S., Norlin, J. M., Gyllensvärd, H. & Schmitt-Egenolf, M. (2023). Mortality in generalized pustular psoriasis: a population-based national register study [Letter to the editor]. The Journal of American Academy of Dermatology, 89(3), 616-619
Åpne denne publikasjonen i ny fane eller vindu >>Mortality in generalized pustular psoriasis: a population-based national register study
Vise andre…
2023 (engelsk)Inngår i: The Journal of American Academy of Dermatology, ISSN 0190-9622, E-ISSN 1097-6787, Vol. 89, nr 3, s. 616-619Artikkel i tidsskrift, Letter (Annet vitenskapelig) Published
sted, utgiver, år, opplag, sider
Elsevier, 2023
Emneord
epidemiology, generalized pustular psoriasis, health care register, Kaplan-Meier survival, mortality, population-based
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-211818 (URN)10.1016/j.jaad.2023.04.066 (DOI)37230364 (PubMedID)2-s2.0-85162924801 (Scopus ID)
Tilgjengelig fra: 2023-07-11 Laget: 2023-07-11 Sist oppdatert: 2023-11-13bibliografisk kontrollert
Tufvesson Stiller, H., Schmitt-Egenolf, M., Fohlin, H. & Uppugunduri, S. (2023). Patient reported experiences of Swedish patients being investigated for cancer during the Covid-19 pandemic. Supportive Care in Cancer, 31(7), Article ID 416.
Åpne denne publikasjonen i ny fane eller vindu >>Patient reported experiences of Swedish patients being investigated for cancer during the Covid-19 pandemic
2023 (engelsk)Inngår i: Supportive Care in Cancer, ISSN 0941-4355, E-ISSN 1433-7339, Vol. 31, nr 7, artikkel-id 416Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Patient reported experiences in individuals being investigated for cancer have been recorded in a nationwide survey in Sweden, providing an opportunity to assess the impact of the Covid-19-pandemic.

Material and Methods: Questionnaires from 45920 patients were analyzed to assess the experience of being investigated for cancer. Data from before the Covid-19-pandemic (2018–2019) was compared to data acquired during the pandemic (2020–2021), using chi-square and Wilcoxon rank sum tests. Both, patients who were cleared from suspicion of cancer and those who were diagnosed with cancer were included.

Results: Fewer patients in total visited health services during the pandemic. However, patients that did seek help did so to a similar extent during as prior to the pandemic. Patient waiting time was perceived to be shorter during the pandemic and judged as neither too long nor too short by most patients. The emotional support to patients improved during the pandemic, whereas the support to next of kin declined. A majority of patients received the results from the investigation in a meeting with the physician. Although there was a preference for receiving results in a meeting with the physician, the pandemic has brought an increasing interest in receiving results by phone.

Conclusion: Swedish cancer healthcare has shown resilience during the Covid-19-pandemic, maintaining high patient satisfaction while working under conditions of extraordinary pressure. Patients became more open to alternatives to physical “in person” health care visits which could lead to more digital visits in the future. However, support to significant others demands special attention.

sted, utgiver, år, opplag, sider
Springer Nature, 2023
Emneord
Cancer, Covid-19, Emotional support, Oncology, Patient reported experience measures, Patient satisfaction
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-211789 (URN)10.1007/s00520-023-07897-y (DOI)001017657700003 ()37354327 (PubMedID)2-s2.0-85162781593 (Scopus ID)
Tilgjengelig fra: 2023-07-12 Laget: 2023-07-12 Sist oppdatert: 2023-07-12bibliografisk kontrollert
Löfvendahl, S., Norlin, J. M., Ericson, O., Hanno, M. & Schmitt-Egenolf, M. (2023). Prolonged sick leave before and after diagnosis of generalized pustular psoriasis: a swedish population-based register study. Acta Dermato-Venereologica, 103, Article ID adv6497.
Åpne denne publikasjonen i ny fane eller vindu >>Prolonged sick leave before and after diagnosis of generalized pustular psoriasis: a swedish population-based register study
Vise andre…
2023 (engelsk)Inngår i: Acta Dermato-Venereologica, ISSN 0001-5555, E-ISSN 1651-2057, Vol. 103, artikkel-id adv6497Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The aim of this study was to analyse sick leave in generalized pustular psoriasis, the most severe form of pustular psoriasis. Prolonged sick leave of >14 days was analysed for 502 patients with generalized pustular psoriasis compared with controls with psoriasis vulgaris and matched controls from the general population. Using data from the Swedish National Patient Register, and the Longitudinal integrated database for health insurance and labour market studies, the study estimated the mean number of sick leave days in the year of first diagnosis of generalized pustular psoriasis (index year) and for 2 years before and after the index year. Patients with generalized pustular psoriasis were on sick leave to a larger extent than both control populations for all study years. The number of sick leave days peaked in the index year and then reduced. Compared with the control populations, sick leave in generalized pustular psoriasis was already higher prior to diagnosis, indicating delayed diagnosis and/or a comorbidity burden.

sted, utgiver, år, opplag, sider
Medical Journals Sweden, 2023
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-214605 (URN)10.2340/actadv.v103.6497 (DOI)37707292 (PubMedID)2-s2.0-85171231695 (Scopus ID)
Tilgjengelig fra: 2023-09-27 Laget: 2023-09-27 Sist oppdatert: 2023-09-27bibliografisk kontrollert
Blauvelt, A., Gondo, G. C., Bell, S., Echeverría, C., Schmitt-Egenolf, M., Skov, L., . . . Strober, B. (2023). Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities. Journal of Psoriasis and Psoriatic Arthritis, 8(3), 100-106
Åpne denne publikasjonen i ny fane eller vindu >>Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities
Vise andre…
2023 (engelsk)Inngår i: Journal of Psoriasis and Psoriatic Arthritis, ISSN 2475-5303, Vol. 8, nr 3, s. 100-106Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Psoriasis severity has traditionally been categorized as mild, moderate, and severe. Commonly, cut-offs for severe disease require a body surface area (BSA) involvement of ≥10% or a Psoriasis Area Severity Index (PASI) > 10. However, clinical experience challenges these traditional measures and requirements, as patients with less extensive psoriasis may have disease that severely impacts quality of life.

Objective: The objective of the present study was to further explore the extent of patient burden when psoriasis affects special locations.

Methods: A total of 69,190 individuals living in the U.S were invited to participate in a patient advocacy survey by telephone and or web interviews over the course of 3 years (2019-2021). The survey instrument consisted of validated patient-reported outcome measures, measuring disease-specific quality of life (Dermatology Life Quality Index, DLQI), depression (Patient Health Questionnaire (PHQ)-2 and (PHQ)-9), and the ability to participate in social roles and activities (PROMIS Ability to Participate in Social Roles and Activities (SF-4a). Chi-square tests were performed to explore association between psoriasis involvement on special locations and patient outcomes and multivariate logistic regression models were then constructed, to assess impact of having psoriasis on special locations patient outcomes, controlling for potential confounding factors.

Results: A total of 4129 individuals completed the survey. 3594 (84.4%) of patients surveyed reported psoriasis involving special areas of the bodysuch as the scalp, face, hands, feet, or genitalia. Involvement of special areas is associated with worse quality of life and depression. 35-71% of patients with 10% or less total BSA involvement experienced a moderate-to-extremely large effect on these life function domains. When adjusting for age, sex, and body surface area, psoriasis involvement of a special location was associated with poorer patient reported outcomes. including a 46% less likelihood of reporting their skin disease ass having “no or only a small effect on QoL,” a 30% less likelihood of having a “normal l ability to participate in social roles and activities,” and a 126% higher likelihood of f having depression.

Conclusion: Real-world data presented here demonstrate that psoriasis involving special areas is associated with adverse life consequences, including poor quality of life and depression.

sted, utgiver, år, opplag, sider
Sage Publications, 2023
Emneord
disease severity, mental health, psoriasis, quality of life, treatment
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-206464 (URN)10.1177/24755303231160683 (DOI)2-s2.0-85150955324 (Scopus ID)
Tilgjengelig fra: 2023-04-06 Laget: 2023-04-06 Sist oppdatert: 2023-12-05bibliografisk kontrollert
Schmitt-Egenolf, M. (2023). The disruptive force of real-world evidence. Journal of Clinical Medicine, 12(12), Article ID 4026.
Åpne denne publikasjonen i ny fane eller vindu >>The disruptive force of real-world evidence
2023 (engelsk)Inngår i: Journal of Clinical Medicine, E-ISSN 2077-0383, Vol. 12, nr 12, artikkel-id 4026Artikkel i tidsskrift, Editorial material (Annet vitenskapelig) Published
sted, utgiver, år, opplag, sider
MDPI, 2023
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-212058 (URN)10.3390/jcm12124026 (DOI)2-s2.0-85163989843 (Scopus ID)
Tilgjengelig fra: 2023-07-18 Laget: 2023-07-18 Sist oppdatert: 2023-07-18bibliografisk kontrollert
Norlin, J. M., Löfvendahl, S. & Schmitt-Egenolf, M. (2023). The influence of socioeconomic factors on access to biologics in psoriasis. Journal of Clinical Medicine, 12(23), Article ID 7234.
Åpne denne publikasjonen i ny fane eller vindu >>The influence of socioeconomic factors on access to biologics in psoriasis
2023 (engelsk)Inngår i: Journal of Clinical Medicine, E-ISSN 2077-0383, Vol. 12, nr 23, artikkel-id 7234Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Since the introduction of biologics for psoriasis, uptake has been uneven and limited. Few studies have investigated the influence of socioeconomic factors on access to biologics.

Objective: To investigate how socioeconomic factors influenced access to biologics.

Methods: Biologic-naïve patients in the Swedish National Register for Systemic Treatment of Psoriasis (PsoReg) for the years 2006–2014 were included. For patients who remained on nonbiologic treatments during their entire registration (n = 1851), the most recent registration was analyzed. For patients who began treatment with biologics during registration in PsoReg (n = 665), the last observation before initiation of biologics was analyzed. A logistic regression model was used to investigate whether education and income influenced the probability of a switch to biologics, whilst adjusting for demographic and individual factors such as age, sex, disease severity, and clinical characteristics.

Results: The odds ratio of access to biologics was 1.8 (CI = 1.3–2.6) in the group with a high level of disposable income, compared with the middle-income group. No differences were found concerning educational levels. The odds ratios of access to biologics decreased with age. Patients with psoriatic arthritis had odds ratios of access to biologics which were more than 50 percent higher, controlling for other variables. High disease severity, in terms of physician- and patient-reported severity, increased the odds ratios of access to biologics.

Conclusions: The higher-income group had better access to biologics than the middle-income group when adjusting for disease severity and lifestyle factors. This may not only be an equity problem, as a better allocation of society’s resources might have resulted in a higher overall effectiveness of biologics.

sted, utgiver, år, opplag, sider
MDPI, 2023
Emneord
access, biologics, DLQI, PASI, psoriasis, socioeconomic
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-218294 (URN)10.3390/jcm12237234 (DOI)001116953900001 ()38068286 (PubMedID)2-s2.0-85179372437 (Scopus ID)
Forskningsfinansiär
Swedish National Board of Health and WelfareSwedish Association of Local Authorities and RegionsStiftelsen Psoriasisfonden
Tilgjengelig fra: 2023-12-22 Laget: 2023-12-22 Sist oppdatert: 2023-12-22bibliografisk kontrollert
Norlin, J. M., Löfvendahl, S. & Schmitt-Egenolf, M. (2023). The use of IL-17 and IL-23 inhibitors in Swedish clinical practice: a register-based analysis. Dermatology, 239(2), 262-266
Åpne denne publikasjonen i ny fane eller vindu >>The use of IL-17 and IL-23 inhibitors in Swedish clinical practice: a register-based analysis
2023 (engelsk)Inngår i: Dermatology, ISSN 1018-8665, E-ISSN 1421-9832, Vol. 239, nr 2, s. 262-266Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND: Interleukin (IL) inhibitors have made completely cleared skin achievable for many patients with moderate to severe psoriasis in clinical trial settings. Few observational studies assess treatment response in accordance with treatment goals in guidelines.

OBJECTIVES: The aim of the study was to analyze the treatment response of IL-17/IL-23 inhibitors in clinical practice and the proportions of patients that reach the treatment target of the Psoriasis Area and Severity Index (PASI) < 3 and the Dermatology Life Quality Index (DLQI) ≤5.

METHODS: A longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Psoriasis, PsoReg. Patients using IL-17/IL-23 inhibitors with assessments of PASI, DLQI, and EQ-5D before (maximum 6 months) and after (3-12 months) initiation of IL-17/IL-23 were included.

RESULTS: In total, 333 patients using IL-17/IL-23 inhibitors were included. Eighty percent (n = 266) received IL-17 inhibitors, and 20% (n = 67) received IL-23 inhibitors. Sixty-six percent of patients reached both PASI <3 and DLQI ≤5, 23% reached one target, and 11% reached none. The mean (SD) PASI, DLQI, and EQ-5D improvements were 6.75 (6.99), 7.14 (7.97), and 0.126 (0.296), respectively. There was no statistically significant difference in outcomes between IL-17 and IL-23 inhibitor treatment groups.

CONCLUSIONS: IL-17/IL-23 inhibitors are effective in clinical practice, but there is still an unmet therapeutic need in moderate to severe psoriasis.

sted, utgiver, år, opplag, sider
S. Karger, 2023
Emneord
DLQI, EQ-5D, Interleukin inhibitors, PASI, Psoriasis
HSV kategori
Forskningsprogram
dermatologi och venereologi
Identifikatorer
urn:nbn:se:umu:diva-201766 (URN)10.1159/000528007 (DOI)000898408100001 ()36516805 (PubMedID)2-s2.0-85145581075 (Scopus ID)
Tilgjengelig fra: 2022-12-16 Laget: 2022-12-16 Sist oppdatert: 2023-07-14bibliografisk kontrollert
Organisasjoner
Identifikatorer
ORCID-id: ORCID iD iconorcid.org/0000-0002-3858-8474